A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Neramexane is a new substance that exhibits antagonistic properties at α9α10 cholinergic nicotinic receptors and N-methyl-D-aspartate receptors, suggesting potential efficacy in the treatment of tinnitus. METHODS: A total of 431 outpatients with moderate to severe subjective tinnitus (onset 3-18 months before screening) were assigned randomly to receive either placebo or neramexane mesylate (25 mg/day, 50 mg/day and 75 mg/day) for 16 weeks, with assessment at 4-week intervals. The primary (intention-to-treat) efficacy analysis was based on the change from baseline in Week 16 in the total score of the adapted German short version of the validated Tinnitus Handicap Inventory questionnaire (THI-12). RESULTS: Compared with placebo, the largest improvement was achieved in the 50 mg/d neramexane group, followed by the 75 mg/d neramexane group. This treatment difference did not reach statistical significance at the pre-defined endpoint in Week 16 (p = 0.098 for 50 mg/d; p = 0.289 for 75 mg/d neramexane), but consistent numerical superiority of both neramexane groups compared with placebo was observed. Four weeks after the end of treatment, THI-12 scores in the 50 mg/d group were significantly better than those of the controls. Secondary efficacy variables supported this trend, with p values of < 0.05 for the 50 mg/d neramexane group associated with the functional-communicational subscores of the THI-12 and the assessments of tinnitus annoyance and tinnitus impact on life as measured on an 11-point Likert-like scale. No relevant changes were observed for puretone threshold, for tinnitus pitch and loudness match, or for minimum masking levels. The 25 mg/d neramexane group did not differ from placebo. Neramexane was generally well tolerated and had no relevant influence on laboratory values, electrocardiography and vital signs. Dizziness was the most common adverse event and showed a clear dose-dependence. CONCLUSIONS: This study demonstrated the safety and tolerability of neramexane treatment in patients with moderate to severe tinnitus. The primary efficacy variable showed a trend towards improvement of tinnitus suffering in the medium- and high-dose neramexane groups. This finding is in line with consistent beneficial effects observed in secondary assessment variables. These results allow appropriate dose selection for further studies. TRIAL REGISTRATION: ClinicalTrials.gov NCT00405886.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Psychoacoustic Measures of Tinnitus
Henry, J. A., & Meikle, M. B. (2000) · Journal of the American Academy of Audiology · doi:10.1055/s-0042-1748040 · Cited by 275 · cited 2×
“This finding is consistent with publications confirming that the tinnitus suffering as perceived is not systematically dependent on audiometrically derived measures of tinnitus loudness and pitch [4-7].”
BackgroundResult
Cited by
Baguley, D., McFerran, D., & Hall, D. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60142-7 · Cited by 1,245
Therapeutic approaches to the treatment of tinnitus
Langguth, B., Elgoyhen, A. B., & Cederroth, C. R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021556 · Cited by 129
Adamchic, I., Tass, P., Langguth, B., Hauptmann, C., Koller, M., Schecklmann, M., Zeman, F., & Landgrebe, M. (2012) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-10-79 · Cited by 79
“Accordingly, several recent clinical trials used a patient-rated CGI change as outcome criterium [32,33].”
Metadata
- Authors
- Suckfüll, M., Althaus, M., Ellers-Lenz, B., Gebauer, A., Görtelmeyer, R., Jastreboff, P. J., Moebius, H. J., Rosenberg, T., Russ, H., Wirth, Y., & Krueger, H.
- Venue
- BMC Ear, Nose and Throat Disorders
- Published
- 2011-01-11
- Volume
- 11
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1472-6815 (ISSN-L)
- OpenAlex
- W1969843575
- Cited by
- 62
- References
- 1
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus. https://app.cochat.ai/papers/10.1186/1472-6815-11-1
- The paper
- Suckfüll, M., Althaus, M., Ellers-Lenz, B., Gebauer, A., Görtelmeyer, R., Jastreboff, P. J., Moebius, H. J., Rosenberg, T., Russ, H., Wirth, Y., & Krueger, H. (2011). A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus. BMC Ear, Nose and Throat Disorders. https://doi.org/10.1186/1472-6815-11-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.